Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Inclusion Criteria: * Histologically proven diagnosis of prostate cancer * Evidence of PSA progression despite castrate levels of testosterone (\<50 ng/dL) following orchiectomy or during therapy with luteinizing hormone releasing hormone agonists (LHRH-a) * Patients with non-metastatic or stable metastatic disease * Chromogranin A elevation above normal range (confirmed by a second evaluation at least 1 week later) \[cut off levels will be \> 20 U/L for enzyme linked immunosorbent (ELISA) assay and \> 100 ng/ml for immunoradiometric (IRMA) assay\] Exclusion Criteria: * Patients who according to the investigator opinion are candidates to be treated immediately with chemotherapy (e.g. docetaxel) * First line treatment with antiandrogen in monotherapy * Visceral metastasis * Previous or concomitant treatment with a somatostatin analogue